Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-3512676 + erlotinib
- Development stage
- Phase 2
- Lead developer
- Pfizer
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
PF-3512676 (also known as CPG 7909) is a synthetic oligodeoxynucleotide that acts as an agonist of Toll-like receptor 9 (TLR9), stimulating the immune system and enhancing immune activation in multiple tumor types. Erlotinib is a small molecule tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR), blocking its activity and thereby inhibiting cancer cell proliferation and survival. The combination of PF-3512676 with erlotinib was investigated for potential synergistic effects in treating advanced non-small cell lung cancer (NSCLC), particularly in EGFR-positive patients, based on their complementary mechanisms—immune activation by PF-3512676 and EGFR inhibition by erlotinib. However, clinical trials did not demonstrate improved progression-free survival with the combination compared to erlotinib alone[2].
- Other names
- erlotinib
02
Targets
EGFR (Epidermal growth factor receptor)TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on PF-3512676 + erlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-3512676 + erlotinib.